Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Takes License to Fundamental Gene-Silencing Patent

Premium

Alnylam Pharmaceuticals this week announced that it has taken a non-exclusive license to RNAi-related intellectual property held by UK technology management firm Plant Bioscience Limited.

As reported by Gene Silencing News, PBL was recently awarded a patent that broadly covers the use of small RNAs to trigger post-transcriptional gene silencing and is based on the pioneering work of the Sainsbury Laboratory researchers David Baulcombe and Andrew Hamilton (GSN 3/8/2012).

PBL, which is jointly owned by the Sainsbury Laboratory, the John Innes Center, and the UK's Biotechnology and Biological Sciences Research Council, has made it a goal to non-exclusively license the intellectual property to as many parties as possible, PBL Managing Director Jan Chojecki said at the time.

The Alnylam deal “endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners through our non-exclusive licensing strategy in agricultural, research, diagnostic, and therapeutic commercial applications,” he said in a statement this week.

Terms of the arrangement were not disclosed.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.